About KANNALIFE SCIENCES INC.
Kannalife Sciences, Inc., a subsidiary of Neuropathix, Inc., is a biopharmaceutical company focused on the research and development of next-generation therapeutics targeting inflammation, neurodegeneration, and neuropathic pain. The company has secured significant grants from organizations such as the Michael J. Fox Foundation and NIH.
Research and development of novel cannabinoid therapeuticsPre-clinical drug discovery and developmentDevelopment of proprietary CBD-like molecules with improved pharmacokinetic and pharmacodynamic profilesConducting clinical trials for the treatment of conditions such as CIPN, HE, mTBI, and chronic painLicensing and commercialization of U.S. Government Patents related to cannabinoids
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to KANNALIFE SCIENCES INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.